AI 聊天

Polyrizon Ltd.

PLRZ · NasdaqCM · USD

11.03 +0.38 (3.57%)

收盘价: Sep 17, 2026, 3:59 PM

市值
$25.26M

Polyrizon Ltd.(PLRZ)股价、分析与数据

内在价值

正在加载内在价值…

分析师预测

股票预测 →

分析师预测不可用

12个月目标价 · n/a 位分析师

分析师一致意见: n/a

时间间隔:1D
正在加载K线和信号…

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收n/an/a
每股收益(TTM)n/an/a

下次财报

查看财报详情 →

指标

买价
7.66
市值
25.3M
净利润(TTM)
-3.33M
n/a
-4.89
n/a
n/a
市净率(TTM)
0.82
市销率(TTM)
n/a
财报日期
n/a
卖价
11.78
成交量
159,379
20日均量
65,535
开盘价
11.60
前收盘价
10.65
日内区间
9.20 - 11.60
52周区间
2.88 - 18.20
分红
n/a
除息日
n/a

关于 Polyrizon Ltd.

查看公司资料 →
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel. Biotechnology · Healthcare

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

板块 Healthcare
上市日期 Oct 29, 2024
员工人数 2
交易所 NasdaqCM
股票代码 PLRZ